Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Pharmacy Benefit Management topic

No spam. Unsubscribe anytime.

Kentucky highlights single PBM model and oversight; some rebate mechanics flagged for follow-up

2401781 · February 26, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

DMS officials described the single pharmacy benefit manager model (MedImpact) created under Senate Bill 50 and said the contract centralizes reporting and rebates to the department; officials will verify whether any rebates are not captured in DMS reporting.

Department for Medicaid Services officials told the Health Budget Review Subcommittee that Kentucky now uses a single pharmacy benefit manager (PBM) model to manage pharmacy benefits for managed-care and fee-for-service Medicaid members.

Jennifer Dudinsky and Commissioner Lisa Lee described the current arrangement: "We do have one single PBM. It's MedImpact," Lee said, referencing the post-Senate Bill 50 procurement that consolidated pharmacy management. Under the model, DMS said MedImpact administers pharmacy claims reporting and rebate collection for the department; the agency also retains responsibility for oversight and reporting to the legislature.

Why this matters: Pharmacy costs are a significant portion of Medicaid spending; consolidation of PBM functions affects how rebates, utilization metrics and top drug spend are tracked and reported to state officials.

What DMS said: The department described two separate contracts held by MedImpact: one to serve the managed-care organizations and another for fee-for-service pharmacy administration. DMS staff said MedImpact reports prescription volume, provider types and top medications by spend and by volume. DMS also said a pharmacy and therapeutics technical advisory committee helps review medications for coverage decisions.

Concerns and follow-up: Committee members asked whether any rebates might bypass DMS reporting. Lee said most rebates are collected by the department but noted physician-administered drugs billed through a different claims channel "may be carved out" and could have separate rebate mechanics; she agreed to double-check and confirm whether any rebates are not reported to DMS. The committee also sought metrics on the PBM's performance and any corrective actions taken; DMS said it will provide the requested documentation.

Ending: DMS characterized the single-PBM model as improving efficiency relative to previous arrangements with multiple MCO-specific PBMs, and agreed to provide additional PBM reporting and rebate reconciliation details to committee staff.